US7307067B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compositions for reducing viral genome amounts in a target cell
Assignee: Leland Stanford Junior University
•
Filing: 2005-05-03
•
Granted: 2007-12-11
•
Expires: 2025-05-03
Abstract
Abstract Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target cell. Also provided are pharmaceutical compositions, kits and systems for use in practicing the subject methods. The subject invention finds use in a variety of applications, including the treatment of subjects suffering from a viral mediated disease condition, e.g., an HCV mediated disease condition.
Inventors
- 👤 Peter Sarnow
- 👤 Catherine L. Jopling
- 👤 Alissa M. Lancaster
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 21:05
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1131; A; A61; A61K; A61K31/00; A61K31/70; A61K31/7088; A61K45/00; A61K45/06; A61K9/00; A61K9/0012; A61K9/0019; A61P; A61P1/00; A61P1/16; A61P31/00; A61P31/12; A61P31/14; A61P31/20; A61P43/00; C12N15/111; C12N2310/00; C12N2310/10; C12N2310/11; C12N2310/113; C12N2310/14; C12N2310/141; C12N2310/30; C12N2310/32; C12N2310/321; C12N2320/00; C12N2320/30; C12N2320/31; C12N2320/50; C12N2330/00; C12N2330/10; C12N2770/00; C12N2770/00011; C12N2770/24011; C12N2770/24211
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
61 words
A method of reducing the amount of Hepatitis C virus replication in a target cell, said method comprising: introducing into a target cell infected with Hepatitis C virus, a miRNA inhibitory agent targeted to miR-122 in an amount sufficient to decrease the activity of miR-122 in said target cell, wherein said miRNA inhibitory agent comprises an antisense oligonucleotide complementary to miR-122.
Claim 2
Independent Claim
61 words
A method of reducing the amount of Hepatitis C virus replication in a target cell, said method comprising: introducing into a target cell infected with Hepatitis C virus, a miRNA inhibitory agent targeted to miR-122 in an amount sufficient to decrease the activity of miR-122 in said target cell, wherein said miRNA inhibitory agent comprises an antisense oligonucleotide complementary to miR-122.
Claim 3
Dependent Claim
14 words
The method according to claim 1 , wherein said target cell is in vitro.
Claim 4
Dependent Claim
14 words
The method according to claim 1 , wherein said target cell is in vivo.
Claim 5
Dependent Claim
23 words
The method according to claim 3 , wherein said method comprises administering the miRNA inhibitory agent to a subject comprising said target cell.
Claim 6
Dependent Claim
20 words
The method according to claim 4 , wherein said method comprises treating said subject for an HCV mediated disease condition.
Claim 7
Independent Claim
66 words
A method of reducing the amount of Hepatitis C virus replication in a target cell, said method comprising: introducing into a target cell infected with Hepatitis C virus, a miRNA inhibitory agent targeted to miR-122 in an amount sufficient to decrease the activity of miR-122 in said target cell, wherein said miRNA inhibitory agent is an antisense oligonucleotide comprising a nucleotide sequence of SEQ ID NO:18.
Claim 8
Independent Claim
66 words
A method of reducing the amount of Hepatitis C virus replication in a target cell, said method comprising: introducing into a target cell infected with Hepatitis C virus, a miRNA inhibitory agent targeted to miR-122 in an amount sufficient to decrease the activity of miR-122 in said target cell, wherein said miRNA inhibitory agent is an antisense oligonucleotide comprising a nucleotide sequence of SEQ ID NO:18.
Claim 9
Dependent Claim
14 words
The method according to claim 6 , wherein said target cell is in vitro.
Claim 10
Dependent Claim
14 words
The method according to claim 6 , wherein said target cell is in vivo.
Claim 11
Dependent Claim
23 words
The method according to claim 8 , wherein said method comprises administering the miRNA inhibitory agent to a subject comprising said target cell.
Claim 12
Dependent Claim
20 words
The method according to claim 8 , wherein said method comprises treating said subject for an HCV mediated disease condition.
Claim 13
Dependent Claim
19 words
The method according to claim 6 , wherein the antisense oligonucleotide comprises a nucleotide sequence of SEQ ID NO:15.
Claim 14
Dependent Claim
19 words
The method according to claim 1 , wherein the antisense oligonucleotide comprises a nucleotide sequence of SEQ ID NO:18.
Claim 15
Dependent Claim
19 words
The method according to claim 1 , wherein the antisense oligonucleotide comprises a nucleotide sequence of SEQ ID NO:15.
Claim 16
Independent Claim
63 words
A method of reducing the amount of Hepatitis C virus replication in a target cell in vitro, said method comprising: introducing into a target cell infected with Hepatitis C virus, a miRNA inhibitory agent targeted to miR-122 in an amount sufficient to decrease the activity of miR-122 in said target cell, wherein said miRNA inhibitory agent is an antisense oligonucleotide complementary to miR-122.
Claim 17
Independent Claim
63 words
A method of reducing the amount of Hepatitis C virus replication in a target cell in vitro, said method comprising: introducing into a target cell infected with Hepatitis C virus, a miRNA inhibitory agent targeted to miR-122 in an amount sufficient to decrease the activity of miR-122 in said target cell, wherein said miRNA inhibitory agent is an antisense oligonucleotide complementary to miR-122.
Claim 18
Dependent Claim
19 words
The method according to claim 14 , wherein the antisense oligonucleotide comprises a nucleotide sequence of SEQ ID NO:18.
Claim 19
Dependent Claim
19 words
The method according to claim 14 , wherein the antisense oligonucleotide comprises a nucleotide sequence of SEQ ID NO:15.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2010-12-10 | 2011-06-11 | 2011-12-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2014-12-10 | 2015-06-11 | 2015-12-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2018-12-10 | 2019-06-11 | 2019-12-11 | $7700.00 | Window Closed / Lapsed |